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Natural killer and natural killer-like T cell lymphomas
represent a rare type of non-Hodgkin’s lymphoma ori-
ginally described to involve the upper aerodigestive
tract. This malignancy has been increasingly observed
in other extranodal sites, particularly in the skin. Pa-
tients with cutaneous natural killer cell lymphoma gen-
erally have a poor prognosis; however, the etiology and
the underlying molecular pathogenesis remain unclear.
This study aimed to investigate comprehensively geno-
mic changes in blastic natural killer and extranodal
natural killer-like T cell lymphoma with cutaneous
involvement. Comparative genomic hybridization
showed chromosome imbalances in six of eight cases
studied (75%). The mean number of chromosome im-
balances per sample was 2.1871.63 with similar number
of gains (1.1871.17) and losses (1.0071.34).The most fre-
quent DNA copy number changes observed were losses
of 9/9p (83%), followed by loss of 13q and gain of 7
(67%). Similar patterns of chromosome imbalances
were observed in both blastic natural killer and cuta-
neous natural killer-like T cell lymphomas. Loss of the
RB1 gene at 13q14.2 was detected in one blastic natural
killer cell lymphoma with 13q loss using a gene dosage
assay, and in one cutaneous natural killer-like T cell
lymphoma without 13q loss using £uorescent in situ hy-
bridization. Genomic microarray analysis identi¢ed on-
cogene copy number gains of PAK1 and JUNB in three
of four cases studied, and gains of RAF1, CTSB, FGFR1,
and BCR in two cases. Real-time polymerase chain re-
action detected ampli¢cation of CTSB and RAF1 in
four of ¢ve cases analyzed, JUNB and MYCN in three
cases, and REL and YES1 in two cases, respectively. In
conjunction with this study, an extensive literature
search for the published G-banded karyotypes of four
subsets of natural killer cell lymphomas was conducted,
which showed a nonrandom pattern of multiple chro-
mosome aberrations. These results reveal consistent
genetic alterations in cutaneous natural killer cell lym-
phomas, and provide a basis for further investigation
of molecular pathogenesis in this malignancy.
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N
atural killer and natural killer-like T cell lympho-
mas represent a rare type of non-Hodgkin’s lym-
phoma that was originally reported to involve
the upper aerodigestive tract (Chan et al, 1997;
Cheung et al, 1998). This malignancy most fre-
quently occurs in East Asia and Central and South America
(Arber et al, 1993; Ja¡e et al, 1996; Cheung et al, 1998; Chuang et
al, 2000; Ko et al, 2000; Nagasawa et al, 2000), and can be asso-
ciated with Epstein^Barr virus (EBV) (Kanavaros et al, 1993;
Chan et al, 1994; Tsang et al, 1994; Tao et al, 1995). The tumor cells
express the neural cell adhesion molecule, which is recognized by
the CD56 antibody (Ng et al, 1987), and is thought to be involved
in cell to cell interactions, homing mechanisms, and tumor cell
dissemination (Cunningham et al, 1987; Lanier et al, 1991). Natural
killer and natural killer-like T cell lymphomas in other extrano-
dal sites have been increasingly reported in recent years (Chan et
al, 1997, 2001a,b), and about 30% of cases have cutaneous involve-
ment, which is the most frequent site of involvement after the
aerodigestive tract (Ansai et al, 1997; Savoia et al, 1997; Natkunam
et al, 1999, 2000; Cho et al, 2000; El Shabrawi-Caelen et al, 2000;
Mraz-Gernhard et al, 2001). These extranodal lymphomas were
classi¢ed by the Revised European American Lymphoma classi-
¢cation as extranodal natural killer-like T cell lymphoma, nasal
type with a cytotoxic T cell phenotype (Harris et al, 1994; Chan
et al, 2001a). The World Health Organization classi¢cation in-
cludes a separate entity described as blastic natural killer cell lym-
phoma, identical to the entity of primary cutaneous CD4þ,
CD56þ lymphoma (Dummer et al, 1996), without the presence
of T cell or myeloid lineage (Harris et al, 2000; Chan et al,
2001b). More recent studies have suggested that CD4þ, CD56þ
lymphoma, or blastic natural killer cell lymphoma may arise
from transformed cells of the lymphoid-related plasmacytoid
dendritic cell subset or type 2 dendritic cell (DC2) (Brody et al,
1995; DiGiuseppe et al, 1997; Kameoka et al, 1998; Petrella et al,
1999, 2002; Ginarte et al, 2000; Chaperot et al, 2001; Feuillard et
al, 2002; Khoury et al, 2002); however, whether this malignancy
really belongs to DC2 tumor and expresses killer cell inhibitory
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receptors, such as CD158a, CD158b, p70, p140-KIR3DL, and
CD94/natural killerG2A or not remain debating (Bagot et al,
1998, 2001; Nikolova et al, 2002). Clinically, patients with
cutaneous natural killer cell lymphomas usually present with
widespread smooth-surfaced nodules and plaques with a
characteristic violaceous color. The tumors have a predilection
for the trunk but also involve the extremities, the head and
neck, and central nervous system (Ansai et al, 1997;
Savoia et al, 1997; Natkunam et al, 1999, 2000; Cho et al, 2000; El
Shabrawi-Caelen et al, 2000; Mraz-Gernhard et al, 2001; Child
et al, 2003). Histologically, there is a bottom-heavy dermal in¢l-
trate without signi¢cant epidermotropism (Child et al, 2003).
Angiocentricity and red cell extravasation are present together
with numerous blast-like mononuclear cells (Ansai et al, 1997;
Savoia et al, 1997; Natkunam et al, 1999, 2000; Cho et al, 2000; El
Shabrawi-Caelen et al, 2000; Mraz-Gernhard et al, 2001; Siu et al,
2002; Child et al, 2003). The prognosis of natural killer and natur-
al killer-like T cell lymphomas is very poor (Ansai et al, 1997;
Savoia et al, 1997; Natkunam et al, 1999, 2000; Cho et al, 2000;
El Shabrawi-Caelen et al, 2000; Mraz-Gernhard et al, 2001; Siu
et al, 2002; Child et al, 2003). Despite recent progress in de¢ning
the immunopathologic features of this disease, the etiology and
underlying molecular pathogenesis remain unclear.
Previous cytogenetic studies have shown a variety of nonran-
dom chromosomal abnormalities in natural killer cell lympho-
mas (Fernandez et al, 1986; Bassan et al, 1988; Taniwaki et al,
1990; Hart et al, 1992; Oshimi et al, 1993; Gelb et al, 1994; Brody
et al, 1995; Callet-Bauchu et al, 1997; Tien et al, 1997; Kameoka
et al, 1998; Petrella et al, 1999; Wong et al, 1999; Zhang
et al, 1999; Hamaguchi et al, 2001; Leroux et al, 2002); however,
unlike nodal non-Hodgkin’s lymphoma, no recurrent chromo-
some translocations have been identi¢ed in this malignancy.
Most malignancies accumulate a series of genetic events, in-
cluding activation of oncogenes and loss of tumor suppressor
genes, leading to a malignant phenotype. Comparative genomic
hybridization (CGH) is a molecular cytogenetic technique used
to identify chromosomal imbalances representing regions of gain
and loss. Previous CGH studies have shown a variety of DNA
copy number changes in nodal and extranodal lymphomas
(Knuutila et al, 2000; Siu et al, 1999, 2002; Ko et al, 2001).We have
identi¢ed consistent and distinctive patterns of chromosome im-
balances in mycosis fungoides/SeŁ zary syndrome, primary cuta-
neous B cell lymphoma, and primary cutaneous CD30þ
anaplastic large cell lymphoma (CD30þ anaplastic large cell lym-
phoma) (Mao et al, 2002a,b, 2003b,c). Genomic microarray is a
novel genomic analysis technology used to screen rapidly for
genomic imbalances in a tumor genome (Pinkel et al, 1998). Pre-
vious studies have shown oncogene copy number changes in sev-
eral epithelial cancers (Pinkel et al, 1998; Daigo et al, 2001; Hui
et al, 2001, 2002).We have also detected gains and losses of various
di¡erent oncogenes in mycosis fungoides/SeŁ zary syndrome, pri-
mary cutaneous B cell lymphoma and CD30þ anaplastic large
cell lymphoma using genomic microarray technique (Mao et al,
2002b, 2003a,c). There are no data available, however, on cuta-
neous natural killer cell lymphomas.
To address the issues of whether there are consistent genomic
changes in cutaneous natural killer cell lymphomas, we have in-
vestigated eight cases using CGH, genomic microarray and real-
time polymerase chain reaction (real-time PCR). In addition, we
have analyzed the RB1 gene in three cases with 13q loss and one
case without 13q loss using gene polymorphism and gene dosage
assays, and £uorescent in situ hybridization.We have then correlated
these ¢ndings with the results of an extensive literature review.
MATERIALS AND METHODS
Samples The study was approved by St. Thomas’ Hospital Research
Ethics Committee. A total of 11 DNA samples from eight patients with
cutaneous natural killer cell lymphomas were selected for this study based
on clinico-pathologic features, immunophenotype, extensive staging
investigations, and the results of T cell receptor (TCR)/immunoglobulin
(IGH) gene analysis (Table I) (Child et al, 2003). This included four cases
of blastic natural killer lymphoma with a germline con¢guration of the
TCR gene, and four cases of extranodal natural killer-like T cell lymphoma
with a clonal TCR gene rearrangement. Two patients (cases 3 and 5) had
lymph node and bone marrow involvement, and case 3 also had nasal
antrum involvement at presentation. Two other patients (cases 5 and 8) had
leukemia. Immunophenotypic studies demonstrated that all eight cases
studied were CD56 positive. In addition, case 3 had a clonal B cell
population with a rearrangement of the IGH gene, a t(14;18) translocation,
and BCL2 positive staining. Only case 4 was positive for EBVdetected with
in situ hybridization (Child et al, 2003). This study was approved by the St
Thomas’ Hospital Research Ethics Committee for sampling (EC02/089).
CGH DNA was extracted from the skin lesions, peripheral blood
mononuclear cells, lymph nodes, and bone marrow from the patients
with cutaneous natural killer cell lymphomas using standard procedures.
CGH was performed as previously described (Kallioniemi et al, 1994; Mao
et al, 2001, 2002a,b, 2003b,c). At least 10 metaphases were captured
and analyzed on a Leica DMRXA £uorescence microscope (Leica
Mitroskopie und System, Solms, Germany) with a COHU charged-
coupled device camera using MacProbe 4.0 software (Perceptive Scienti¢c
Instruments International Ltd, Chester, UK). The threshold set for gains
corresponded to a mean hybridization ratio between tumor and normal of
greater than 1.25:1, and losses of less than 0.75:1 (Fig 1) (Kallioniemi et al,
1994; Mao et al, 2001, 2002a,b, 2003a,b).
Analysis of the RB1 gene with molecular and £uorescent in situ
hybridization assays To con¢rm CGH ¢ndings on 13q in this study,
two blastic natural killer cell lymphomas (sample nos 1231 and 1683)
and one cutaneous natural killer-like T cell lymphoma sample (no. 1733)
with 13q loss were analyzed using gene polymorphism assay. In this
experiment, 100 ng of tumor DNA was ampli¢ed with the £uorescently
labeled primer sets for Rbi.2 (microsatellite) and RB1.20 (variable
number tandem repeat, VNTR) (Onadim et al, 1992, 1997), and the PCR
products were then analyzed for intragenic RB1 polymorphism using
ALFexpress automatic sequencer (Amersham Biosciences, Bucks, UK).
To assess further the copy number loss of RB1 at a molecular level, a
£uorescent dosage assay was conducted in sample 1231. Brie£y, 100 ng of
tumor DNAwas ampli¢ed with 32 pairs of £uorescently labeled primers,
in 11multiplex reactions, covering all exons with associated splice sites, the
promoter region, 30 untranslated region and the poly(A) site of the entire
RB1 gene (NCBI LocusLink, 2002). The PCR products were analyzed
using ALFexpress (Amersham Biosciences). The RB1 gene dosage was
determined by the dosage quotient. The dosage quotient value between
0.76 and 1.28 was set as the level for disomy (normal gene dosage),
whereas the value between 0.36 and 0.68 was regarded as monosomy
(hemizygosity).
In addition, single-color £uorescent in situ hybridization was carried out
on the available slide containing metaphase chromosomes and interphase
nuclei from case 8 (sample 2634). Brie£y, SpectrumOrange labeled RB1
probe, LSI 13 (Vysis Inc., Downers Grov, Illinois), was applied to the
patient slide, and codenatured on a hot block at 701C for 5 min, and
hybridized at 371C overnight. Posthybridization washing and £uorescent
image analysis were as described previously (Mao et al, 2001, 2002a, 2003a).
Genomic microarray To de¢ne genomic imbalances, four cases of
blastic natural killer cell lymphoma (nos 1, 2, 4, and 6) with noticeable
chromosome imbalances detected by CGH were selected for genomic
microarray analysis. This experiment was conducted as previously
described (Pinkel et al, 1998; Daigo et al, 2001; Hui et al, 2001, 2002;
Mao et al, 2002b, 2003a,c). After probe labeling, hybridization and
posthybridization washes, £uorescent images of the hybridized microarray
chips, AmpliOnc I DNA array (Vysis Inc.), which contains 59 clones from
57 oncogenes (BCL2 and AR are represented by both 50 and 30 genomic
clones) representing genomic regions that have been reported to be
ampli¢ed in human tumors, were captured and analyzed using the
GenoSensor Reader System (Vysis Inc.). The £uorescent ratio threshold
for gains and losses of oncogene copy number were set according to our
control experiments (Mao et al, 2002b, 2003b,c). The measured £uorescent
ratios of oncogenes on autosomes ranged from 0.8 to 1.2 with a mean ratio
of 1 and SD of 0.2 in testing samples. The ratios on AR located at Xq11q12
were beyond 1.25 in normal female to male control sets due to the extra
copy of X chromosome from normal female DNA, and below 0.75 in
normal male to female control sets due to one copy of X chromosome
from male DNA. Therefore a value of 170.2 was set as the level for
disomy (normal gene copy number), whereas ratios greater than 1.25 were
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regarded as cut-o¡ for trisomy (gain of gene copy number), and ratios less
than 0.75 as cut-o¡ for monosomy (loss of gene copy number) (Mao et al,
2002b, 2003a,c).
Real time^PCR To validate further and clarify chromosome imbalances
and genomic imbalances identi¢ed by CGH and genomic microarray in
this study, four cases of blastic natural killer lymphoma (nos 1, 2, 4, and 6)
and one cutaneous natural killer-like T cell lymphoma (case 3) showing
noticeable genomic changes were analyzed using real-time PCR. A total
of seven oncogenes (targets), namely MYNC, REL, RAF1, CTSB, YES1,
BCL2, and JUNB, and two housekeeping genes, B2M and ALB (reference)
were tested (MWG Biotech, High Point, North Caroline) (Table II). This
experiment, based on the Taqman assay (Bieche et al, 1998), was carried out
using the ABI Prism 7700 Sequence Detector System (ABI/Perkin Elmer,
Foster City, California) as previously reported (Mao et al, 2002b,c, 2003b).
The parameter CT is de¢ned as the fractional cycle number at which the
£uorescence generated by cleavage of the probe passes a ¢xed threshold
above baseline. The target gene copy number is quanti¢ed by measuring
CT and by using a standard curve to determine the starting copy number.
The ratio of the target gene copy number to the reference gene copy
number normalizes the amount and quality of genomic DNA. The ratio
de¢ning the level of increased copy number of the target gene was
termed as ‘‘N’’ and was determined as follows: N¼ copy number of target
gene/copy number of reference gene. An N-value greater than 2 was set for
gene ampli¢cation (Mao et al, 2002b, 2003a,c).
Literature review To compare our ¢ndings with previous published
cytogenetic data, we have collated the G-banded karyotypes of peripheral
Table I. A summary of clinico-pathologic and CGH ¢ndings in eight cutaneous natural killer (NK) lymphomas
Case Sample Diagnosis Immunophenotype TCR/IgH2 CGH3
1 1231S Blastic NK CD2þ ,CD4þ,CD8^,CD30,CD56þ ,TIA^1^ pc/pc enh(7),dim(9p13p22,12p12p13,13q14q21)
lymphoma
2 1683S Blastic NK CD2^,CD3^,CD4^,CD8^,CD20^,CD43þ, pc/pc enh(7p),dim(2q35q37,9,13q12q34)
lymphoma CD56þ ,TIA^1þ
3 1733S Cutaneous NK/ CD2þ ,CD3^,CD4^,CD8^,CD20^,CD43þ, c/c dim(3p12p21,9,13q)
T cell lymphoma CD56þ ,TIA^1^
1734B Cutaneous NK/ CD2þ ,CD3^,CD4^,CD8^,CD20^,CD43þ, c/c enh(18)
T cell lymphoma CD56þ ,TIA^1^
1781M Cutaneous NK/ CD2þ ,CD3^,CD4^,CD8^,CD20^,CD43þ, c/c N
T cell lymphoma CD56þ ,TIA^1^
1802L Cutaneous NK/ CD2þ ,CD3^,CD4^,CD8^,CD20^,CD43þ, c/c enh(4,18,19)
T cell lymphoma CD56þ ,TIA^1^
4 1860S Blastic NK CD4þ,CD43þ,^CD56þ pc/^ enh(6p21p22,7q),dim(9p23p24)
lymphoma
5 2022S Cutaneous NK/ CD2þ ,CD3þ,CD4^,CD8þ,CD20^,CD30þ, c/pc N
T cell lymphoma CD43þ,CD56þ,TIA^1^,CD5þ,CD7þ
6 2412S Blastic NK CD4þ,CD30^,CD56þ ,Alk^1^,TIA^1^ pc/^ dim(9,13q14q34)
lymphoma
7 2592S Cutaneous NK/ CD56þ c/^ N
T cell lymphoma
8 2634B Cutaneous NK/ CD56þ c/^ enh(5q33q35,7q33q36,9q),dim(12p11p12)
T cell lymphoma
1 S, skin lesion; B, blood; L, lymph nodes; M, bone marrow.
2 pc, polyclonal (normal); c, clonal (rearrangment); ^, not available.
3 enh, enhanced (gain); dim, diminished (loss); N, normal.
Figure1. Illustration of the original CGH £uorescent image (left) and ratios (right) of case 2 (sample 1683). In the left ¢gure light gray-colored
chromosomes 9 (short arrow) and 13q (long arrow) were clearly visible, and in the right the £uorescent ratios of chromosomes 9 and 13q were below 0.75
indicating losses of 9 and 13q.
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T cell lymphoma/natural killer cell lymphoma, nonspeci¢c, blastic natural
killer cell lymphoma (CD4þ CD56þ DC2), extranodal natural killer-like
T cell lymphoma, nasal type (natural killer/TCL), and aggressive natural
killer cell lymphoma/leukemia (aggressive natural killer cell lymphoma/
leukemia) through an extensive literature search (Fernandez et al, 1986;
Koizumi et al, 1986; Bassan et al, 1988; Sheridan et al, 1988; Taniwaki et al,
1990; Hart et al, 1992; Sun et al, 1992, 1993; Oshimi et al, 1993; Gelb et al,
1994; Brody et al, 1995; Shimodaira et al, 1995; Wong et al, 1995, 1997, 1999,
2000; Callet-Bauchu et al, 1997; DiGiuseppe et al, 1997; Suzuki et al,
1997; Tien et al, 1997; Kameoka et al, 1998; Petrella et al, 1999; Zhang et al,
1999; Hamaguchi et al, 2001; Leroux et al, 2002; Mitelman Database of
Chromosome Aberrations in Cancer, 2002). All chromosome aberrations
were grouped into chromosomal losses and gains, and structural
rearrangements.
RESULTS
CGH Of the eight cases (11 DNA samples) analyzed in this
study, six showed chromosome imbalances (75%). Overall the
mean number of chromosome imbalances per sample was
2.1871.63 with similar number of gains (1.1871.17) and losses
(1.0071.34). The most frequent DNA copy number changes
(minimum three cases) were losses of 9/9p (¢ve of six, 83%),
followed by loss of 13q and gain of 7 (four of six, 67%) (Table I)
(Figs 1^3). Less frequent chromosome imbalances (o 3 cases),
including losses of 2q, 3p, and 12p, and gains of 4, 5q, 6p, 9q, 18,
and 19 were also seen (Table I) (Fig 3). A similar pattern of
chromosome imbalances was present in both blastic natural killer
and cutaneous natural killer-like T cell lymphomas. There was
only one case (no. 3) from which multiple DNA samples were
analyzed. This case showed intratumoral variation in the pattern
of chromosome imbalances, namely, blood (1734) and lymph
node (1802) revealing gain of 18, skin (1733) demonstrating losses
of 3p, 9, and 13q, and bone marrow (1781) having a normal copy
number (Table I).
RB1 assays All three samples (nos 1231, 1683, and 1733) analyzed
using the two intragenic RB1 polymorphic markers, Rbi.2
microsatellite and RB1.20 VNTR, exhibited single alleles with
these polymorphisms. In addition, sample 1231, which was
further analyzed for all RB1 regions (including the promoter
and the 30 untranslated region) using £uorescent dosage
screening, showed hemizygosity across all regions of RB1 tested
(dosage quotient value ranged from 0.32 to 0.63), indicating the
presence of only one copy of the RB1 gene. Furthermore,
£uorescent in situ hybridization analysis of sample 2634 revealed
that 67% of cells had two copies of RB1, and 33% of cells showed
only one copy of RB1 (Fig 4).
Genomic microarray All four cases studied by genomic
microarray showed genomic imbalances (100%). Oncogene copy
number gains of PAK1 and JUNB were observed in three cases,
and RAF1, CTSB, FGFR1, and BCR in two cases (Figs 5 and 6).
There was broad concordance between the results of CGH and
genomic microarray in two cases (Figs 3 and 6). Case 2 (sample
1683) revealed losses of 9 and ABL1 (9q34.1). Case 4 (sample 1860)
had gains of 6p21p22 and MYB (6q22). These two methods also
revealed discordant results in case 6, however, which showed loss
of chromosome 9 by CGH without loss of ABL1 (9q34.1) by
genomic microarray (Figs 3 and 6).
Real-time PCR Of the ¢ve cases analyzed by real-time PCR,
four showed ampli¢cation of CTSB and RAF1 (80%), three had
ampli¢cations of JUNB and MYCN (60%), and two revealed
ampli¢cations of REL and YES1 (40%) (Table III). The pattern
of oncogene ampli¢cation in both blastic natural killer and
cutaneous natural killer-like T cell lymphomas was similar. The
real-time PCR results were consistent with the CGH and
genomic microarray ¢ndings in all these cases (Tables I and III;
Figs 3 and 6). For example, case 2 showed ampli¢cations of
RAF1, CTSB, and JUNB by both real-time PCR and genomic
microarray. Case 3 revealed ampli¢cations of YES1 and BCL2
(18q21.3) by genomic microarray, and gain of 18 by CGH. Case
4 had real-time PCR and genomic microarray evidence of
MYCN, REL, RAF1, CTSB, and JUNB ampli¢cation. Case 6
showed ampli¢cations of JUNB by both real-time PCR and
genomic microarray. Discrepancies between these three
techniques, however, were present in case 1, which showed ampli-
¢cations of RAF1 and CTSB by real-time PCRwithout corres-
ponding chromosomal or oncogene gains by either CGH or
genomic microarray (Tables I and III; Figs 3 and 6).
Literature review The major nonrandom chromosome
abnormalities (same aberration presenting in more than ¢ve
cases) identi¢ed in peripheral T cell lymphoma/natural killer cell
lymphoma nonspeci¢c (Mitelman Database of Chromosome
Aberrations in Cancer, 2002), CD4þ CD56þ DC2 (review
of 32 published cases), natural killer/TCL (review of 19 pub-
lished cases) and aggressive natural killer cell lymphoma/
leukemia (review of 34 published cases) were summarized in
Table IV. Among these subsets of natural killer cell lym-
phomas, peripheral T cell lymphoma/natural killer cell lym-
phoma nonspeci¢c showed multiple aberrations a¡ecting each
individual chromosome, and the most common chromosome
changes (4 10 cases) were gains of chromosomes 3, 5, 7, X,
losses of 9, 14, 6/6q, and 17/17p, and a translocation involving 6p
and 6q (Table IV). Similar chromosome abnormalities were
Table II. A summary of the primers and the probes used in real-time PCR
Gene Forward primer Reverse primer Probe
MYCN CCGCAACGACCTTCGG TCTTTACCAACTCCGGCACG 50 -(FAM)-CCAGCTTTCTCACGCTCAGGGACC-
(TAMRA)-30
REL CCCACGCTCAGGCAATACA CAATCTCAACCCACTGTCAGCTA 50 -(FAM)-ACCCACTGAGTAGTTTTTCAACAAGGA
CACTTCC-(TAMRA)-30
RAF1 CGCTTCCGAGCCATCCTT GTCAGCGTGCAAGCATTGAT 50 -(FAM)-CATCGGGCAGCCCACACTGAGG-(TAMRA)-30
CTSB CATCTCTGACCGGATCTGCA TCCGCCGACACCTCCA 50 -(FAM)-CCACACCAATGCGCACGTCAGC-(TAMRA)-30
YES1 CAAGTGGAGCGAGGATACAGG TCAATTCATGGAGGGATTCTGG 50 -(FAM)-TGCCGTGCCCTCAGGGCTG-(TAMRA)-3’
BCL2 TGGTGGTTTGACCTTTAGAGA AGGTCTGATCATTCTGTTC 50 -(FAM)-CTCTGGGTGGGTCTGTGTTGAAACA-
(TAMRA)-30






ALB AGGGTAAAGAGTCGTCGATATGCT CAATCTCAACCCACTGTCAGCTA 50 -(FAM)-CAAACGCATCCATTCTACCAACTTGAGCAT-
(TAMRA)-30
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present in CD4þ CD56þ DC2, natural killer/TCL and
aggressive natural killer cell lymphoma/leukemia but with
involvement of only a few chromosomes/chromosomal regions
(Table IV). The most frequent chromosome aberrations
observed in CD4þ CD56þ DC2 (45 cases) were losses of
5/5q, 9, 12/12p, 13/13q, and 15, and gain of 6/6q. In natural killer/
TCL the most common chromosome changes (45 cases) were
losses of 2/2q, 6/6q, and Y, and gain of X. Whereas losses of 7
and 10/10p were frequently seen in aggressive natural killer cell
lymphoma/leukemia (45 cases) (Table IV). Overall our CGH
Figure 2. Illustration of a CGH karyotype of case 2.This karyotype was produced by the analysis of 11 high-quality normal metaphase spreads hybri-
dized with the patient’s DNA mixed with equal amount of normal reference DNA, which showed losses of 2q35q37, 9, 13q12q34, and Yq, and gain of 7p.
Figure 3. A summary of the CGH pro¢le of the informative blastic natural killer and cutaneous natural killer-likeTcell lymphoma samples.
This diagram showed losses of 9/9p (¢ve samples), 13q (four samples), 12p (two samples), 2q and 3p (one sample each), and gains of 7 (four samples), 18 (two
samples), 4, 5q, 9q, and 19 (one sample each). Copy number changes on X andYwere used as internal controls to show the e⁄ciency of CGH hybridization.
622 MAO ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
results, such as losses of 2q, 9, 12p, and 13q, and gain of 7
identi¢ed in both blastic natural killer and cutaneous natural
killer-like T cell lymphomas (Table I) (Fig 3), were consistent
with previously cytogenetic ¢ndings (Table IV).
DISCUSSION
Our comprehensive genomic studies of blastic natural killer and
cutaneous natural killer-like T cell lymphoma presenting in the
skin have identi¢ed consistent patterns of genetic alterations.
CGH showed losses of 9/9p in 83% of cases, and loss of 13q and
gain of 7 in 67% of cases. In addition, RB1 assays revealed loss of
this tumor suppressor gene in one blastic natural killer cell lym-
phoma and in one cutaneous natural killer-like T cell lymphoma.
Furthermore, genomic microarray demonstrated oncogene copy
number gains of PAK1 and JUNB in three cases, and gains of
RAF1, CTSB, FGFR1, and BCR in two cases. This was supported
by real-time PCR, which detected ampli¢cation of CTSB, RAF1,
MYCN, JUNB, REL, and YES1 in more than 40% of cases ana-
lyzed. There was a concordance between the results of these tech-
niques, although some discrepancies were also noted, which are
likely to be due to either the di¡erent sensitivity of the techni-
ques or intratumoral heterogeneity. Our extensive literature re-
view also revealed nonrandom chromosome aberrations in four
subsets of natural killer cell lymphomas, including losses of
2/2q, 5/5q, 6/6q, 9, 12/12p, and 13/13q, and gain of 7 (see the refer-
ences cited in Materials and Methods). Our ¢ndings suggest that
these genomic alterations may be critical in the pathogenesis of
both blastic natural killer and cutaneous natural killer-like T cell
lymphomas.
There have been two reports describing genome-wide DNA
copy number changes in natural killer cell lymphomas from the
high incidence areas (Siu et al, 1999; Ko et al, 2001). One study
showed frequent losses of chromosomes 6q, 11q, 13q, and 17p,
and gains of 1p, 6p, 11q, 12q, 17q, 19p, 20q, and Xq in Chinese pa-
tients with nasal natural killer cell lymphoma and aggressive nat-
ural killer cell lymphoma/leukemia (Siu et al, 1999). Another
study revealed frequent gains of 2q, 3q, 5q, 10q, 13q, 17q, and
Figure 4. Illustration of interphase £uorescent in situ hybridization
image of case 8 (sample 2634). In this ¢gure three cells with 2 copies of
RB1 and one cell with 1 copy of RB1were clearly visible.
Figure 5. An original chart of the AmpliOnc I microarray chip hybridized with DNA of case 4 (sample 1860).The tumor (T)/reference (R) ratio
of 19 oncogene clones (MYCL1, NRAS, NMYC, REL, RAF1, PIK3CA, MYB, EGFR, CTSB, FGFR1, FGFR2, HRAS, PAK1, CCND2, KRAS2, INSR,
JUNB, ZNF217, and AR 50) was beyond the threshold of 1.25, indicating gains of these oncogenes. In contrast, the T/R ratio of two clones (MDM2 and
TOP2A) falls below 0.75, indicating losses of these oncogenes.
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21q, and losses of 1p, 6q, 12q, 13q, and 17p in Korean patients with
nasal natural killer/TCL (Ko et al, 2001). East Asia, however, is
one of the areas with the highest rates of EBV infection in the
world (de-The et al, 1975; Henle and Henle, 1980). In addition,
EBV nonrandomly integrates into the human genome, and the
human chromosome integration sites of EBV include chromo-
some bands of 1p31, 1q31, 1q43, 2p22, 2q32, 3q13, 3q28, 4q13,
5p14, 5q12, 6q24, 7q31, and 11p15 (Lestou et al, 1993; Wuu et al,
1996). Therefore, it is di⁄cult to exclude the possibility that these
genetic changes detected in natural killer cell lymphomas are a
result of EBV infection. In contrast, all the patients analyzed in
this study came from the UK, a low incidence area for both
EBV infection and natural killer cell lymphomas, and only one
of eight patients studied was EBV positive. The most intriguing
¢ndings in this study were the identi¢cation using CGH of losses
of chromosomes 9/9p and 13q, and gain of 7, which were present
in both blastic natural killer and cutaneous natural killer-like
T cell lymphomas. These results are consistent with the previous
cytogenetic reports (see the references cited in Materials and Meth-
ods), suggesting that the disruptions of genes on these chromo-
somes may be associated with cutaneous natural killer cell
lymphomas. In addition, these ¢ndings are distinct from our pre-
vious observations in mycosis fungoides/SeŁ zary syndrome, pri-
mary cutaneous B cell lymphoma and CD30þ anaplastic large
Figure 6. A summary of genomic microarray pro¢ling of four blastic natural killer cell lymphomas. This diagram illustrated gains of PAK1,
JUNB, RAF1, CTSB, FGFR1 and BCR.
Table III. Real-time PCR ¢ndings in 5 cutaneous NK lymphomas
N valuea
Case no. Sample no. MYCN REL RAF1 CTSB YES1 BCL2 JUNB
1 1231 0.78 1.95 2.44 4.66 1.51 1.22 0.94
2 1683 2.10 2.88 3.20 3.40 1.45 1.66 4.24
3 1802 2.42 4.59 4.97 1.86 4.35 2.71 1.67
4 1860 2.22 1.73 2.34 5.68 2.00 0.95 3.34
6 2412 0.13 0.14 0.20 2.52 0.63 0.48 2.37
aN¼ amount of PCR product of target gene/reference gene (B2M and ALB).
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cell lymphoma (Mao et al, 2002a,b, 2003b,c), implicating di¡erent
pathogenesis.
In this study, one blastic natural killer cell lymphoma with 13q
loss identi¢ed by CGH showed a deletion of the RB1 gene by
using gene dosage assay. Interestingly, loss of RB1was also present
in 33% of cells from a patient with cutaneous natural killer-likeT
cell lymphoma without showing 13q loss. In this case CGH may
have failed to detect 13q loss because the number of tumor cells
with RB1 loss were below the detection capacity. Other studies
have also shown RB1 deletion and loss of RB1 protein expression
in blastic natural killer cell lymphoma and cell lines (Sakajiri et al,
2001). Taken together these ¢ndings suggest that loss of RB1may
be a common event in the development of cutaneous natural kill-
er cell lymphomas.
There have been few reports of oncogenic abnormalities in
natural killer cell lymphomas in the literature. For example, one
study detected KRAS (12p12.1) mutations in 25% of nasal natural
killer cell lymphomas (Hoshida et al, 2002). In this study,
although loss of 12p was detected in two cases by CGH, no copy
number change of KRASwas seen in these cases. In contrast, am-
pli¢cations of RAF1, CTSB, and JUNB were identi¢ed in over
40% of cases using genomic microarray and real-time PCR. In
addition, our immunophenotypic studies showed expression of
JUNB protein in two cases (Mao et al, 2003a). The pattern of
genomic imbalances in cutaneous natural killer cell lymphomas
was also distinctive from that in primary cutaneous B cell lym-
phoma (Mao et al, 2002b), further implying di¡erent genetic
pathway involved. RAF1 (v-raf-1 murine leukemia viral onco-
gene homolog 1) is a mitogen-activated protein kinase, which acts
downstream of RAS, and is regulated by BCL2 and other apop-
tosis-related proteins (NCBI LocusLink, 2002). CTSB encodes
cathepsin B, a lysosomal cysteine protease that cleaves amyloid
precursor protein and is involved in tumor invasion (NCBI
LocusLink, 2002). Previous studies have shown ampli¢cations of
RAF1 and CTSB in esophageal and urinary bladder carcinomas,
respectively (Hughes et al, 1998; Simon et al, 2001).We have also
identi¢ed ampli¢cations of these oncogenes in mycosis fun-
goides/SeŁ zary syndrome and CD30
þ anaplastic large cell lym-
phoma (Mao et al, 2003a,c). Further functional studies are now
required to assess the potential role of these oncogenic alterations
in the pathogenesis of cutaneous natural killer cell lymphomas.
Intratumoral variation of the pattern of chromosome imbal-
ances has been reported in multiple tumor samples from the in-
dividual patients as evidence of genetic heterogeneity (Jung et al,
1999). In this study, such variation was seen in case 3. DNA sam-
ples from blood and lymph nodes showed gain of 18, and lymph
nodes also had ampli¢cation of BCL2 by real-time PCR. In
contrast, skin sample revealed losses of 3p, 9, and 13q. Whereas
the bone marrow sample did not demonstrate chromosome im-
balances. In addition, conventional cytogenetic analysis of bone
marrow samples detected trisomies 3, 13, and 18 in small number
of cells (data not shown). Interestingly identical Vg1 (TCR) and
VH1 (IGH) clonal rearrangements were identi¢ed in all samples
from skin, blood, lymph node, and bone marrow. This
was further complicated by the detection of a t(14;18) transloca-
tion, in both skin and lymph node. The t(14;18) translocation
is known to occur in the majority of follicular lymphomas
and some di¡use large B cell lymphomas (Weiss et al, 1987). The
clinical and pathologic features in this case were in keeping
with a blastic natural killer cell lymphoma, and B cell markers
were negative but 10% of the neoplastic cells within the in¢ltrate
were CD3, CD8, and TIA-1 positive (Child et al, 2003). These
results suggest the presence of a transformed extranodal
natural killer-likeTcell lymphomawith cytotoxic features (Child
et al, 2003). The presence of a clonal IGH gene rearrangement
could be explained by an anomalous IGH gene rearrangement
in a T cell lymphoma but this would not explain the detection
of a t(14;18) translocation, although this can be detected at very
low levels in healthy individuals (Limpens et al, 1995). Previous
studies have suggested that natural killer-like T cell lymphoma
originate from a T cell lineage (Ng et al, 1987; Macon et al, 1996;
Chan et al, 1997). Our data suggest, however, that both T and B
lineage malignant cells presenting in this cutaneous natural killer-
like T cell lymphoma may result from the molecular defects oc-
curring at the stage of common lymphoid progenitors with the
capacity to develop intoTand B cells (Kondo et al, 1997); this may
represent a genuine composite lymphoma as three additional
cases also showed coexistence of T and B cell lymphomas (data
not shown). Further study is therefore appropriate to clarify this
hypothesis.
In summary, we have identi¢ed a consistent pattern of geno-
mic alterations in cutaneous natural killer cell lymphomas, and
further studies are underway to characterize the candidate genes
using comprehensive genomic and proteomic approaches.
This work was supported by the British Skin Foundation, Dermatrust and St John’s
Special Purpose Fund.
Table IV. Major non-random chromosome aberrations in nat-







1p36þ 5 0 0 0
t(2;5)(p23;q35) 6 0 0 0
^2/2q^ 0 0 5 0
þ 3 17 0 0 0
^3 5 0 0 0
þ 4 5 0 0 0
4q^ 0 0 6 0
þ 5 13 0 0 0
^5/5q^ 6 12 0 0
þ 6/6qþ 0 7 0 0
^6/6q^ 14 0 12 0
t(6;6)(q16;p11) 10 0 0 0
þ 7 10 0 0 0
^7 0 0 0 7
^8 9 0 0 0
^9 10 7 0 0
^10/10p^ 9 0 0 5
^11 7 0 0 0
^12/12p^ 5 7 0 0
^13/13q^ 7 14 0 0
14q32þ 8 0 0 0
^14 10 0 0 0
^15 7 6 0 0
þ 16 5 0 0 0
^16 7 0 0 0
^17/17p^ 11 0 0 0
þ 18 5 0 0 0
^18 7 0 0 0
þ 19 9 0 0 0
^19 7 0 0 0
þ 20 7 0 0 0
þ 21 6 0 0 0
^21 7 0 0 0
þ 22 7 0 0 0
þX 10 0 10 0
^X 6 0 0 0
^Y 8 0 7 0
aCut-o¡ case number45.
bPTL/NKL NOS, peripheral T-cell lymphoma/natural killer cell lymphoma
non-speci¢c.
cCD4þCD56þDC22, CD4þCD56þ type 2 dendritic cell acute leukaemia-
blastic natural killer cell lymphoma.
dNK/TCL, extranodal natural killer-like T-cell lymphoma, nasal type.
eANKCL/L, aggressive natural killer cell lymphoma/leukaemia.
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